medrogestone การใช้

• "' Medrogestone "'( menopausal symptoms and in the treatment of gynecological disorders.
• Although their clinical relevance is uncertain, these actions of medrogestone could contribute to its weak antiandrogen activity.
• It is not known whether medrogestone passes into breast milk, but it is to be expected given its lipophilicity and studies with structurally related progestins.
• In addition, similarly to progesterone, medrogestone can inhibit 5?-reductase " in vitro " in microsomal preparations of skin and prostate.
• It is also related to the 19-norprogesterone derivatives gestonorone caproate, nomegestrol acetate, norgestomet, and segesterone acetate and to the 17?-methylprogesterone derivative medrogestone.
• In addition to the above, various progesterone derivative progestins such as chlormadinone acetate, cyproterone acetate, medrogestone, medroxyprogesterone acetate, megestrol acetate, and segesterone acetate possess weak glucocorticoid activity which can manifest clinically at high dosages.
• They can be categorized into several structural groups, including derivatives of retroprogesterone, 17?-hydroxyprogesterone, 17?-methylprogesterone, and 19-norprogesterone, with a respective example from each group including dydrogesterone, medroxyprogesterone acetate, medrogestone, and promegestone.
• Medrogestone has been found to be an 3?-hydroxysteroid dehydrogenase / ? 5-4 isomerase " in vitro ", preventing conversion of pregnenolone to progesterone and 17?-hydroxypregnenolone to 17?-hydroxyprogesterone in rat testis preparations, and inhibits the biosynthesis of testosterone " in vivo " in rats.